Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BiomX Ltd.

www.biomx.com

Latest From BiomX Ltd.

Asia Deal Watch: Everest Licenses Asia Rights To Calliditas’ IgA Nephropathy Candidate

While an orphan indication in the US and EU, IgAN accounts for 40% of glomerular disease in China; deal also confers rights in Hong Kong, Macau, Taiwan, Singapore. Also, Y-Biologics teams with Dualogics on bispecific antibodies for cancer.

Business Strategies Deals

Seventure Reaffirms Microbiome Confidence With New €200m Fund

With its first microbiome fund completing its investment period, French venture capitalist Seventure Partners has raised more than €100m of a €200m target for its second microbiome-focused fund.

Financing StartUps and SMEs

Venture Funding Deals: Spin-Outs From Axovant, Inovio & Sosei

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced January and February 2019.

Deals Financing

Finance Watch: Scripps Research Models A New Way To Fund Translation

Private Company Edition: Scripps Research has a new model for translating academic findings into drugs, including a novel fund for financing that work. Also, in venture capital deals, Oyster Point closes a $93m Series B round and Peloton raises a $150m Series E.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Gastrointestinal
  • Hepatic (Liver)
  • Alias(es)
  • MBcure
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • BiomX Ltd.
  • Senior Management
  • Jonathan Solomon, CEO
    Sigal Fattal, CFO
    Naomi B Zak, PhD, Pres. & COO
    Assaf Oron, CBO
    Sailaja Puttagunta, MD, CMO
    Merav Bassan, PhD, Chief Dev. Officer
  • Contact Info
  • BiomX Ltd.
    Phone: 723942377
    7 Pinhas Sapir St., Fl. 2
    Ness Ziona, 7414002
    Israel
Advertisement
Advertisement
UsernamePublicRestriction

Register